Sign In
Buy ARGX
$813.14
+10.97 (+1.37%)
At Close: Jun 03, 2026
argenex SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts
03:28am, Sunday, 12'th Apr 2026
Shares of argenex SE (NASDAQ: ARGX - Get Free Report) have earned a consensus rating of "Moderate Buy" from the twenty-four brokerages that are covering the firm, Marketbeat reports. Four equities res
SG Americas Securities LLC Has $2.67 Million Stock Holdings in argenex SE $ARGX
05:01am, Saturday, 04'th Apr 2026
SG Americas Securities LLC increased its stake in argenex SE (NASDAQ: ARGX) by 94.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 3,179 shares o
Allspring Global Investments Holdings LLC Sells 38,598 Shares of argenex SE $ARGX
03:22am, Tuesday, 31'st Mar 2026
Allspring Global Investments Holdings LLC trimmed its position in shares of argenex SE (NASDAQ: ARGX) by 18.3% during the fourth quarter, according to its most recent disclosure with the Securities an
CSLLY or ARGX: Which Is the Better Value Stock Right Now?
12:41pm, Tuesday, 24'th Mar 2026
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both CSL Limited Sponsored ADR (CSLLY) and argenex SE (ARGX). But which of these two companies is the bes
eClinical Solutions elluminate® Platform Supports argenx to Enhance Data Oversight and Efficiency
09:00am, Tuesday, 24'th Mar 2026
BOSTON--(BUSINESS WIRE)--eClinical Solutions LLC, a global provider of digital clinical software and services, today announced that argenx SE, a global immunology company, is expanding adoption of the
CSLLY vs. ARGX: Which Stock Is the Better Value Option?
12:40pm, Monday, 23'rd Mar 2026
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either CSL Limited Sponsored ADR (CSLLY) or argenex SE (ARGX). But which of these two stocks is more
Alkeon Capital Management LLC Grows Stock Position in argenex SE $ARGX
03:28am, Sunday, 15'th Mar 2026
Alkeon Capital Management LLC grew its holdings in argenex SE (NASDAQ: ARGX) by 133.3% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The instituti
Positive results from Phase 3 ADAPT OCULUS study show VYVGART's potential as the first targeted treatment for patients living with ocular MG Additional data from ADAPT SERON – the largest study of p
KMDA vs. ARGX: Which Stock Is the Better Value Option?
12:40pm, Thursday, 05'th Mar 2026
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Kamada (KMDA) and argenex SE (ARGX). But which of these two stocks presents investors wi
argenx CEO Karen Massey Reaffirms Vision 2030, Teases VYVGART Catalysts at TD Cowen Conference
01:32am, Thursday, 05'th Mar 2026
argenx (NASDAQ: ARGX) used a fireside chat at the TD Cowen Health Care Conference to outline its near- and longer-term priorities, with incoming CEO Karen Massey emphasizing that the company's strateg
Baron Health Care Fund Q4 2025 Contributors And Detractors
10:18am, Tuesday, 03'rd Mar 2026
Eli Lilly and Company's shares rose during the quarter as Zepbound's obesity launch continued to gain strong traction. Cidara Therapeutics' shares rose further following Merck's acquisition of the com
argenex Q4 Earnings Call Highlights
05:16am, Sunday, 01'st Mar 2026
argenx (NASDAQ: ARGX) used its fourth-quarter earnings call to highlight positive Phase 3 data in ocular myasthenia gravis (MG), continued commercial momentum for VYVGART, and its first year of annual
These Analysts Revise Their Forecasts On Argenx After Q4 Earnings
08:48am, Friday, 27'th Feb 2026
Argenx SE (NASDAQ: ARGX) on Thursday reported upbeat fourth-quarter results and announced positive topline results from the Phase 3 ADAPT OCULUS study evaluating VYVGART in adults with ocular myasthen
Baron International Growth Fund Q4 2025: Contributors, Detractors, And Trades
06:50am, Friday, 27'th Feb 2026
For 2025, we underperformed the Benchmark, while to a lesser extent also trailing our all-cap international growth Proxy Benchmark. The underperformance was in our view attributable to an abrupt but m
Artisan Partners Limited Partnership Sells 163,266 Shares of argenex SE $ARGX
03:16am, Friday, 27'th Feb 2026
Artisan Partners Limited Partnership trimmed its position in shares of argenex SE (NASDAQ: ARGX) by 6.9% in the undefined quarter, according to the company in its most recent filing with the Securitie
